You are here

P&T News

November 26

Company says move aimed at thwarting counterfeiters
Fewer than half of HIV-positive young adults know they are infected
Decision follows ‘thumbs down’ from advisory panel
Treatment superior to ustekinumab in moderate-to-severe plaque psoriasis
Researchers develop compression protocol based on pressure rather than force

November 25

Dry-delivery technique eliminates need for needles, liquid storage
Agency recommends adding important safety information to product labels
First fixed-combination clindamycin/benzoyl peroxide medication for once-daily treatment
Drug captures almost half of second-line share among newly diagnosed patients

November 24

‘Team-based care’ might be the solution
Monoclonal antibody increases number of deaths in phase III trial
Patterns of genetic activity could help in early detection

November 21

GAPVAC trial matches vaccines to individual glioblastoma patients
Tablet is difficult to crush, break, or dissolve for illicit use
‘The crisis is worsening,’ editorial writers say
No approved vaccines are available for this indication
Surgical membrane heals damage with vitamin A derivative

November 20

Seventy percent response rate observed in ongoing phase II study
Oncologists expected to embrace lower-cost alternatives to Neupogen
Price of Sovaldi caught payers by surprise, expert says

November 19

FDA submission expected later this year

November 18

Equipment could be ‘game-changer’ in glioblastoma treatment
Researchers investigate famciclovir/celecoxib combo
NIH studies find limited kidney benefit from more rigorous blood pressure treatment

November 17

Treatment improves progression-free survival compared with chemotherapy alone
Presence of type-1 interferon helps guide treatment choices
More than 80% of patients show no progression of joint structural damage
Approval based on data from two pivotal studies
Second virus-related death in U.S.

November 14

New testing sought for Mallinckrodt and Kudco Ireland ADHD drugs
Two-day meeting of experts seeks to prioritize global efforts
Improper contact lens habits pose major risk for serious infections
Approval decision expected early next year with ‘priority review’
Results are obtained within 90 minutes

November 13

Experts clarify areas of agreement across multiple guidelines
TNF-alpha inhibitors face competition from biosimilars
No FDA-approved meds can counteract antiplatelet effect
Analysis combines questionnaire, genetic profiling, and mammography scans

Pages

P&T TV

From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.

Interview

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.

Meetings